Detalhe da pesquisa
1.
Sequencing strategies in the new treatment landscape of prostate cancer.
Future Oncol
; 15(25): 2967-2982, 2019 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-31424285
2.
Activity and safety of metronomic cyclophosphamide in the modern era of metastatic castration-resistant prostate cancer.
Future Oncol
; 15(10): 1115-1123, 2019 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-30887825
3.
Abiraterone acetate and its use in the treatment of metastatic prostate cancer: a review.
Future Oncol
; 14(5): 431-442, 2018 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-29350549
4.
Enzalutamide after chemotherapy in advanced castration-resistant prostate cancer: the Italian Named Patient Program.
Future Oncol
; 14(26): 2691-2699, 2018 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-30207488
5.
Long-term clinical impact of PSA surge in castration-resistant prostate cancer patients treated with abiraterone.
Prostate
; 77(9): 1012-1019, 2017 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-28429372
6.
Weekly paclitaxel after first-line failure in patients with advanced non-small-cell lung cancer: everyday clinical practice in a single centre.
Anticancer Drugs
; 28(6): 654-659, 2017 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-28252532
7.
Serial 18F-choline-PET imaging in patients receiving enzalutamide for metastatic castration-resistant prostate cancer: response assessment and imaging biomarkers.
Future Oncol
; 12(3): 333-42, 2016 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-26768648
8.
Clinical outcomes in octogenarians treated with docetaxel as first-line chemotherapy for castration-resistant prostate cancer.
Future Oncol
; 12(4): 493-502, 2016 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-26776493
9.
Metabolic syndrome in castration-resistant prostate cancer patients treated with abiraterone.
Prostate
; 75(12): 1329-38, 2015 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-25982919
10.
Safety and clinical outcomes of patients treated with abiraterone acetate after docetaxel: results of the Italian Named Patient Programme.
BJU Int
; 115(5): 764-71, 2015 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-24988879
11.
Gastrointestinal metastases from prostate cancer: a review of the literature.
Future Oncol
; 11(4): 691-702, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-25686122
12.
Prognostic and predictive factors in patients treated with chemotherapy for advanced urothelial cancer: where do we stand?
Future Oncol
; 11(1): 107-19, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-25572786
13.
Intermittent docetaxel chemotherapy as first-line treatment for metastatic castration-resistant prostate cancer patients.
Future Oncol
; 11(6): 965-73, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-25760977
14.
Impact of visceral metastases on outcome to abiraterone after docetaxel in castration-resistant prostate cancer patients.
Future Oncol
; 11(21): 2881-91, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-26436290
15.
Integrating mHealth in Oncology: Experience in the Province of Trento.
J Med Internet Res
; 17(5): e114, 2015 May 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-25972226
16.
Potential value of rapid prostate-specific antigen decline in identifying primary resistance to abiraterone acetate and enzalutamide.
Future Oncol
; 10(6): 985-93, 2014 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-24941984
17.
Emerging role of tumor-associated macrophages as therapeutic targets in patients with metastatic renal cell carcinoma.
Cancer Immunol Immunother
; 62(12): 1757-68, 2013 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-24132754
18.
Chemotherapy in metastatic renal cell carcinoma today? A systematic review.
Anticancer Drugs
; 24(6): 535-54, 2013 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-23552469
19.
The Role of Fast and Deep PSA Response in Castration-sensitive Prostate Cancer.
Anticancer Res
; 42(1): 165-172, 2022 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34969722
20.
To treat or not to treat: is it acceptable to avoid active therapies in advanced prostate cancer today?
Expert Rev Anticancer Ther
; 21(4): 389-400, 2021 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-33245666